Greenwich Biosciences is focused on discovering, developing, and commercializing novel therapeutics from its propriety cannabinoid product platform. Our enduring commitment to scientific rigor and exacting pharmaceutical manufacturing standards enables us to bring forward plant-derived cannabinoid prescription medicines for patients. We are the first and only company to pursue and receive FDA approval for a plant-derived cannabinoid therapy that addresses difficult-to-treat conditions with significant unmet needs. It is our passion and purpose to continually seek solutions that transform the lives of those living with rare and severe neurological diseases. For additional information, please visit www.GreenwichBiosciences.com.